Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis (MASH) study, while still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback